Incyte Corp.
Steven H Stein (CMO & Head of Late-Stage Dev.) sells INCY shares
AI-generated summary
Steven H Stein, CMO & Head of Late-Stage Dev. at Incyte Corp., acquired 240,193 shares through option exercises for a value of $19,543,823.67 and sold 240,193 shares in open-market sales for a total value of $28,435,748.42. Following these transactions, the insider directly held 30,916 shares. The transactions were executed under a Rule 10b5-1 trading plan.
Key facts
- Insider
- Steven H Stein · CMO & Head of Late-Stage Dev.
Rule 10b5-1 plan
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Nov 6, 2026 | M · exercise or conversion of a derivative | +8,539 | $68.62 | $585,946.18 | 39,455 | Direct |
| Nov 6, 2026 | M · exercise or conversion of a derivative | +12,335 | $72.27 | $891,450.45 | 51,790 | Direct |
| Nov 6, 2026 | M · exercise or conversion of a derivative | +16,428 | $80.50 | $1,322,454.00 | 68,218 | Direct |
| Nov 6, 2026 | M · exercise or conversion of a derivative | +15,054 | $74.78 | $1,125,738.12 | 83,272 | Direct |
| Nov 6, 2026 | M · exercise or conversion of a derivative | +23,526 | $77.67 | $1,827,264.42 | 106,798 | Direct |
| Nov 6, 2026 | M · exercise or conversion of a derivative | +18,331 | $61.76 | $1,132,122.56 | 125,129 | Direct |
| Nov 6, 2026 | M · exercise or conversion of a derivative | +19,749 | $61.18 | $1,208,243.82 | 144,878 | Direct |
| Nov 6, 2026 | M · exercise or conversion of a derivative | +12,305 | $64.25 | $790,596.25 | 157,183 | Direct |
| Nov 6, 2026 | M · exercise or conversion of a derivative | +6,907 | $68.25 | $471,402.75 | 164,090 | Direct |
| Nov 6, 2026 | M · exercise or conversion of a derivative | +16,428 | $85.01 | $1,396,544.28 | 180,518 | Direct |
| Nov 6, 2026 | M · exercise or conversion of a derivative | +12,743 | $90.56 | $1,154,006.08 | 193,261 | Direct |
| Nov 6, 2026 | M · exercise or conversion of a derivative | +15,054 | $83.58 | $1,258,213.32 | 208,315 | Direct |
| Nov 6, 2026 | M · exercise or conversion of a derivative | +24,838 | $83.20 | $2,066,521.60 | 233,153 | Direct |
| Nov 6, 2026 | M · exercise or conversion of a derivative | +879 | $113.64 | $99,889.56 | 234,032 | Direct |
| Nov 6, 2026 | M · exercise or conversion of a derivative | +17,986 | $113.64 | $2,043,929.04 | 252,018 | Direct |
| Nov 6, 2026 | M · exercise or conversion of a derivative | +19,091 | $113.64 | $2,169,501.24 | 271,109 | Direct |
| Nov 6, 2026 | S · open-market saleFootnotes F1 | −35,042 | $116.06 | $4,067,086.65 | 236,067 | Direct |
| Nov 6, 2026 | S · open-market saleFootnotes F2 | −22,336 | $117.14 | $2,616,550.72 | 213,731 | Direct |
| Nov 6, 2026 | S · open-market saleFootnotes F3 | −60,270 | $118.27 | $7,128,307.68 | 153,461 | Direct |
| Nov 6, 2026 | S · open-market saleFootnotes F4 | −73,969 | $119.12 | $8,811,009.75 | 79,492 | Direct |
| Nov 6, 2026 | S · open-market saleFootnotes F5, F6 | −48,576 | $119.66 | $5,812,793.61 | 30,916 | Direct |
| Nov 6, 2026 | M · exercise or conversion of a derivativeEmployee Stock Option (right to buy)Footnotes F7 | −8,539 | $0.00 | $0.00 | 1 | Direct |
| Nov 6, 2026 | M · exercise or conversion of a derivativeEmployee Stock Option (right to buy)Footnotes F8 | −12,335 | $0.00 | $0.00 | 0 | Direct |
| Nov 6, 2026 | M · exercise or conversion of a derivativeEmployee Stock Option (right to buy)Footnotes F9 | −16,428 | $0.00 | $0.00 | 0 | Direct |
| Nov 6, 2026 | M · exercise or conversion of a derivativeEmployee Stock Option (right to buy)Footnotes F10 | −15,054 | $0.00 | $0.00 | 0 | Direct |
| Nov 6, 2026 | M · exercise or conversion of a derivativeEmployee Stock Option (right to buy)Footnotes F11 | −23,526 | $0.00 | $0.00 | 2,139 | Direct |
| Nov 6, 2026 | M · exercise or conversion of a derivativeEmployee Stock Option (right to buy)Footnotes F12 | −18,331 | $0.00 | $0.00 | 10,054 | Direct |
| Nov 6, 2026 | M · exercise or conversion of a derivativeEmployee Stock Option (right to buy)Footnotes F13 | −19,749 | $0.00 | $0.00 | 10,831 | Direct |
| Nov 6, 2026 | M · exercise or conversion of a derivativeEmployee Stock Option (right to buy)Footnotes F14 | −12,305 | $0.00 | $0.00 | 18,783 | Direct |
| Nov 6, 2026 | M · exercise or conversion of a derivativeEmployee Stock Option (right to buy)Footnotes F15 | −6,907 | $0.00 | $0.00 | 20,722 | Direct |
| Nov 6, 2026 | M · exercise or conversion of a derivativeEmployee Stock Option (right to buy)Footnotes F16 | −16,428 | $0.00 | $0.00 | 0 | Direct |
| Nov 6, 2026 | M · exercise or conversion of a derivativeEmployee Stock Option (right to buy)Footnotes F17 | −12,743 | $0.00 | $0.00 | 0 | Direct |
| Nov 6, 2026 | M · exercise or conversion of a derivativeEmployee Stock Option (right to buy)Footnotes F18 | −15,054 | $0.00 | $0.00 | 0 | Direct |
| Nov 6, 2026 | M · exercise or conversion of a derivativeEmployee Stock Option (right to buy)Footnotes F19 | −24,838 | $0.00 | $0.00 | 2,258 | Direct |
| Nov 6, 2026 | M · exercise or conversion of a derivativeIncentive Stock Option (right to buy)Footnotes F20 | −879 | $0.00 | $0.00 | 0 | Direct |
| Nov 6, 2026 | M · exercise or conversion of a derivativeNon-Qualified Stock Option (right to buy)Footnotes F20 | −17,986 | $0.00 | $0.00 | 0 | Direct |
| Nov 6, 2026 | M · exercise or conversion of a derivativeNon-Qualified Stock Option (right to buy)Footnotes F21 | −19,091 | $0.00 | $0.00 | 0 | Direct |
Footnotes
- F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.56 to $116.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.64 to $117.63 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.64 to $118.635 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.64 to $119.63 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.65 to $119.79 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F6 This includes an aggregate of 29,338 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.
- F7 Beginning July 2, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
- F8 Beginning January 4, 2019, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2019 and the remainder vesting monthly over three years.
- F9 Beginning January 17, 2020, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2020 and the remainder vesting monthly over three years.
- F10 Beginning January 19, 2022, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2022 and the remainder vesting monthly over three years.
- F11 Beginning July 2, 2022, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
- F12 The July 14, 2023 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
- F13 Beginning January 18, 2024, options become exercisable in 37 installments, with the first 25% vesting on July 14, 2024 and the remainder vesting monthly over three years.
- F14 The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
- F15 The July 15, 2025 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
- F16 Beginning July 2, 2019, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
- F17 Beginning January 15, 2021, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2021 and the remainder vesting monthly over three years.
- F18 Beginning July 2, 2021, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
- F19 Beginning January 20, 2023, options become exercisable in 37 installments, with the first 25% vesting on July 2, 2023 and the remainder vesting monthly over three years.
- F20 Beginning January 17, 2017, options become exercisable in full on January 17, 2021.
- F21 Beginning January 17, 2017, options become exercisable in 37 installments, with the first 25.00% vesting on July 15, 2017 and the remainder vesting monthly over three years.
More INCY filings
- 144
Filed Nov 6, 2026
- 4
Filed Nov 5, 2026
- 144
Filed Nov 3, 2026
- 10-Q
Filed Oct 29, 2026
- 8-K
Filed Oct 29, 2026
- 4
Filed Oct 19, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.